RecruitingPhase 1NCT06452160

A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors

Sponsor

BridGene Biosciences Inc.

Enrollment

103 participants

Start Date

Jun 27, 2024

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Mesothelioma Epithelioid Hemangioendothelioma(EHE)

Summary

The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called BGC515 in people with advanced cancers that have not responded to standard treatments, with a focus on mesothelioma (a cancer of organ linings), epithelioid hemangioendothelioma (a rare vascular tumor), and other solid tumors with specific genetic abnormalities. **You may be eligible if...** - You are 18 or older with advanced mesothelioma, epithelioid hemangioendothelioma, or another solid tumor that has progressed on standard treatment - You are in good to moderate health (ECOG score 0 or 1) - You have at least one measurable tumor on imaging - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have previously used a TEAD inhibitor drug - You have not adequately recovered from side effects of previous cancer treatments - You have severe heart, kidney, or other organ problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.